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Abstract

ADHD is one of the most commonly diagnosed disorders during adolescence. Recently,
significant increases in the diagnosis of ADHD have caused the prescription of the ADHD
medication methylphenidate (MPH) to increase. MPH is a psychostimulant that blocks the
dopamine transporter, which is responsible for dopamine reuptake at the synapse. The blockade
of the dopamine transporter results in an increase in the availability of dopamine in the synaptic
cleft. This increase of dopamine accounts for the addictive properties of a MPH due to strong
effects on portions of the brain’s drug-reward pathway, including the striatum and nucleus
accumbens. In this study, we hypothesized that dopamine D2 receptor antagonism would block
MPH-induced conditioned place preference. We also hypothesized this will be more effective in
adolescent male rats as compared to adolescent female rats based on evidence that has shown a
higher density of dopamine D2 receptors in the brain’s reward areas of adolescent male rats. The
effects of MPH on the associative effects of MPH was analyzed using the conditioned place
preference (CPP) behavioral paradigm. Results showed that MPH-induced CPP was not blocked
by the dopamine D2 receptor antagonist, likely due to its effects on the inhibitory presynaptically
located dopamine D2 autoreceptor. The importance of these findings is discussed relative to the
role of the D2 receptor in MPH addiction.
Keywords: Methylphenidate, MPH, dopamine, D2 receptor, antagonist
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Analysis of the role of D2 receptors in methylphenidate-induced conditioned place preference

Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed
disorders in adolescence, and is characterized by increased impulsivity, hyperactivity, and
inattentiveness (Goldman, Genel, Bezman, & Slanetz, 1998). It is suspected that this disorder
affects from two to sixteen percent of school-aged children, and effects three to five percent of
children globally (Rader, McCauley, & Callen, 2009; Nair, Ehimare, Beitman, Nair, & Lavin,
2006). Children who are affected by ADHD will have difficulties with decision making,
motivational issues, behavioral inhibition, temporal rewards, and may engage in riskier activities
when compared to their peers (Toplak, Jain, & Tannock, 2005; Nikolas & Nigg, 2013). As can
be understood, ADHD can prove to be a significant impairment for adolescent children if it is not
properly treated. As such, a number of different treatment options have come into existence, but
the most prevalent form of therapy for ADHD is by medication through psychostimulants
(Swanson, Baler, & Volkow, 2011).
One of the most commonly prescribed medications for ADHD is the psychostimulant
methylphenidate (MPH) (Trade name: Ritalin; Wu et al., 2012). MPH has a therapeutic effect on
ADHD symptoms as a product of working on the dopamine system by blocking the dopamine
transporter, a protein that is implicated in the reuptake of the dopamine neurotransmitter from the
synaptic cleft for their return to the presynaptic neuron (Schweri et al., 1995). Similarly, MPH
also produces slight effects on the levels of another neurotransmitter, norepinephrine, by
blocking the norepinephrine transporter (Solanto, 1998). This transporter behaves similarly to
the dopamine transporter relative to the norepinephrine system. In the case of blockade of either
of these two transporters that MPH effects, the result is an excess of the neurotransmitter in the
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synaptic cleft, resulting in a diminished synaptic clearance of these neurotransmitters. This
diminished clearance leaves abnormally high amounts of these neurotransmitters in the synaptic
cleft. As with MPH, and many other drugs, this can lead to unwanted or deleterious effects for
the person who is using these agents.
Dopamine plays a central role in modulating the brain’s reward and pleasure systems,
while norepinephrine plays a role in regulating mood. Additionally, dopamine is closely
associated with the presentation of reward-seeking behaviors including approach, consumption,
and addiction (Nestler, 2005). Drugs that are commonly abused by humans such as opiates,
ethanol, nicotine, amphetamine, and cocaine show an increase in the dopamine levels within the
mesolimbic system, with especially high concentrations found in the nucleus accumbens (Di
Chiara & Imperato, 1988). Additionally, there are five identified dopamine receptors: D1, D2,
D3, D4, and D5 (Niznik & Van Tol, 1992). These receptors come in two different subtypes: the
D1-like subtype, comprised of D1 and D5 receptors, and the D2-like subtype, comprised of the D2,
D3, and D4 receptors (Vallone, Picetti & Borrelli, 2000). Subsequent findings have revealed that
the main distinction between the two different subtypes is based on the effects these receptors
have on the second messenger cyclic adenosine monophosphate, as well as their differences in
pharmalogical profiles (Kebabian & Caine, 1979). Despite having differing pharmalogical
properties, both families of dopamine receptors are affected when using MPH (Swanson &
Volkow, 2003). Due to the fact that MPH enhances dopamine activity, the two families of
dopamine receptors should be studied to further the understanding about the effects of MPH on
the dopamine system, as well as their effect on the reinforcing behaviors.
Whereas it is widely accepted that MPH is an effective treatment for ADHD and
pervasive developmental disorders, investigations on the effects of MPH are critically important
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(Reichow, Volkmar, & Bloch 2013). This is because MPH has been shown to have addictive
liabilities, due to increases in available synaptic dopamine (Bogle & Smith, 2009). Furthermore,
the use of a dopamine transporter blockade gives MPH a neuropharmacological profile that is
similar to that of cocaine (Volkow et al., 1999). In addition to cocaine, MPH interacts with and
activates the same drug-reward pathway that drugs such as nicotine and amphetamine do
(Swanson & Volkow, 2002; Yang, Swann, & Dafny, 2006). The interaction with the drugreward pathway that results in the increase of dopamine-related activity is prevalent in two
particular brain regions, the striatum and nucleus accumbens. Additionally, MPH has also been
shown to produce significant increases in locomotor activity, a behavior that is mediated by the
nucleus accumbens and striatum (Salamone & Correa, 2002). Locomotor activity can simply be
defined as the movement from one place to another, and, in experimental contexts, it may be
measured to gauge reward-seeking behavior. The similarities in the properties and effects of
commonly abused rewarding drugs, such as cocaine and amphetamine, to the properties of MPH,
show the addictive potential of MPH.
It has been shown that MPH is used recreationally as an addictive agent. This is due to
the fact that this drug is a stimulant. When taken recreationally, MPH is typically taken orally or
snorted (Teter, McCabe, LaGrange, Cranford, & Boyd, 2006). In the case of snorting MPH, this
route avoids the body’s first pass metabolism by the liver, which delivers higher concentrations
of the drug to the brain when compared to taking the drug orally. The results of avoiding first
pass metabolism will be a more intense drug effect that typically has a faster onset. Due to the
fact that people both frequently use and abuse this drug, one could consider it a major concern
for public health due to a possibility that long-term effects on the brain could be present
(Carlezon & Konradi, 2004). Consequently, further studies on the long and short-term effects of
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MPH use are desperately needed to ensure that using medication with MPH is not having a
damaging effect on the brain.
Additionally, our laboratory has also shown the use of MPH causes an increase in
neurotrophic factors (Brown et al., 2012). Neurotrophic factors are cellular growth factors that
are important for synaptic maintenance and growth, and they have been separated into three main
families: the neurotrophins, the glial-cell derived neurotrophic factor (GDNF) family, and the
neuropeptidic cytokines (Boyd & Gordon, 2003). For example, in vivo studies using
neurotrophic factors have been responsible for neurogenesis of mammalian neurons in two
different brain regions (Hagg, 2009). However, despite the fact that neurotrophic factors
facilitate the proper functioning and efficiency of neurons, significant increases of neurotrophic
factors does not always correlate with flourishing and healthy neurons. In fact, elevated
neurotrophic factor levels appear to play a role in the drug craving response, especially when
these elevated levels are found within the mesolimbic pathway (Pickens et al., 2011). For
example, increased neurotrophic factors in the mesolimbic pathway have been shown in people
who use cocaine, attesting to the idea that this increase plays a role in addiction (Grimm et al.,
2003).
Of the three families of neurotrophic factors discussed above, the family most pertinent to
our study is the neurotrophin family. The mammalian neurotrophin family of growth factors
contains four different types: nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) (Lessmann, Gottmann, &
Malcangio, 2003). All four different types of neurotrophins play a wide variety of roles for
different bodily functions throughout mammalian development, and changes in the secretion
rates and overall levels of these growth factors are implicated in a diverse array of disease states
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including Alzheimer’s disease, depression, pain, and asthma (Allen & Dawbarn, 2006).
Additionally, Allen and Dawbarn (2006) note that one particular growth factor, BDNF, plays a
special role in activity-dependent synaptic plasticity, something that could be indicative of either
learning occurring or memory formation. Typically learning and memory formation is a sign of
proper function of neurons, but in the context of drug addiction, it proves to be the fuel to help
this maladaptive process set in. This growth factor, BDNF, is of primary interest for this
particular study.
BDNF is a growth factor protein that is found throughout the central nervous system that
helps to support the survival of neurons, as well as to promote the growing of new synapses in
the brain (Conner, Lauterborn, Yan, Gall, & Varon, 1997). When describing the role and effect
of BDNF, authors Robert Julien, Claire Advokat, and Joseph Comaty (2010) write, “…when
injected into the brain of rats, BDNF not only prevents the spontaneous death of some neurons,
but also helps to protect neurons that have been poisoned with various toxins. Conversely, in
animals, chronic stress decreases the production and amount of BDNF (and other neurotrophic
substances) in the brain and increases cell death.” This excerpt shows that BDNF is critical to
neural functioning, so, naturally, a lack of this neurotrophic factor can be severe in consequence.
Interestingly, Corominas-Roso et al. (2013) have also reported that, “Low BDNF levels may
contribute to the neurodevelopmental deficits of ADHD and to the persistence of the disorder
into adulthood.” This finding is extremely interesting because it gives more information on why
MPH works so well as an ADHD medication. By using MPH, you increase BDNF levels
throughout the brain, and, with respect to these findings, this increase may also be part of the
therapeutic action that MPH takes when alleviating symptoms of ADHD. However, it should be
noted that polarization of BDNF levels in either direction can cause deleterious effects on the
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brain, and that the healthiest level of this protein can be found in the middle ground. In this
study, we will be harvesting brain tissues from two dominant areas in the drug-reward pathway,
the nucleus accumbens and the striatum, and we will be running a chemical analysis to determine
the amount of BDNF in these tissue samples.
Another interesting and important area to consider when trying to fully understand the
effects of MPH with D2 antagonism is sex differences. Our laboratory has shown that a
relatively high dose of MPH (5mg/kg) (a dose which is comparable to dose taken by addicts,
rather than medicinal users) results in robust sex differences in the behavioral response to this
drug (Chase, Carrey, Soo, & Wilkinson, 2007; Brown et al., 2012). This data shows that
adolescent female rats demonstrate a 100% increase in locomotor activity compared to
adolescent males given the same dose at peak responding, and the results from this study indicate
that female adolescent rats sensitized to MPH, whereas males administered the same dose and
regimen of MPH failed to produce sensitization (Brown, et al., 2012). Drug sensitization is a
phenomenon produced by psychostimulants when an increased behavioral effect of a drug occurs
following repeated doses. In essence, drug sensitization is the opposite of acquiring a drug
tolerance, which means that the female adolescent rats may have a higher sensitivity to the
addictive properties of MPH as compared to adolescent male rats. These behavioral and
pharmacological results indicate a raised probability that dopamine-dense brain areas will have
increased sensitivity to the addictive properties of MPH (Meredith, Callen, & Scheuer, 2002).
In our present study, we intend to investigate the neurobehavioral mechanisms of the
rewarding effects of MPH by focusing on the dopamine D2 receptor to evaluate its role in this
phenomenon. We will assess the role of D2 receptors in MPH-induced CPP by conditioning rats
in a five day CPP behavioral paradigm. By using a D2 receptor antagonist (eticlopride), we will
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reduce the functionality of the D2 receptors, and subsequently gauge whether or not MPHinduced CPP occurs. Following a posttest to see whether or not CPP has occurred, brain tissues
will be taken to be analyzed for BDNF concentrations within the nucleus accumbens and
striatum. Finally, group differences will be analyzed using ANOVA. Our hypothesis is that the
use of eticlopride, the dopamine D2 antagonist, will block CPP produced by MPH in adolescent
rats, and that this will be more effective in adolescent male rats as compared to adolescent
female rats. This hypothesis is based on work by Andersen & Teicher (2000) that have reported
a higher density of dopamine receptors in the striatum of males during adolescence when
compared to adolescent female rats. This study will add to the information on the underlying
actions and mechanisms of the rewarding effects of MPH.
Method
Participants
The animals for this experiment arrived at East Tennessee State University at postnatal
day 21 (p21) and were ordered from Harlan, Inc (Indianapolis, IN, USA). In total, there were 45
subjects (23 female, 22 male) in our study. All rats were housed in an AAALAC-accredited
animal facility at East Tennessee State University with a 12 hour on/off light/dark cycle. Food
and water were available ad libitum.
Research Design
Animals were divided into four separate experimental groups: a low dose eticlopride
group (0.01 mg/kg), a high dose eticlopride group (0.03 mg/kg), MPH (5 mg/kg) group, and the
saline control group. Both eticlopride groups were administered eticlopride followed 15 minutes
later by MPH, whereas the MPH group was first given an intraparitoneal (ip) injection dose of
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saline followed 15 minutes later by MPH. Approximately 10-15 minutes after MPH injection,
animals were placed into their respective conditioning contexts, which were randomly assigned.
Saline control groups received two injections of saline. By analyzing two doses of eticlopride,
we can compare the differences between the low dose and high dose of eticlopride, which will
help discern dose-dependent effects of this drug. The incorporation of MPH and saline groups
will allow for the comparison of the D2 antagonist groups with MPH relative to CPP.
Materials and Procedure
The CPP apparatuses measure 90 cm on each side, and are divided into three equivalent
sized compartments. In our lab, we have two CPP apparatuses that are placed directly beside one
another, and the three contexts are separated by removable wooden dividers. By doing this, we
are able to simultaneously condition multiple animals in order to help facilitate the time spent
during conditioning trials.
Additionally, each one of the individual compartments is separated by a removable
wooden divider that is only removed during both the pretest and posttest of the experiment. A
picture of this CPP box setup can be viewed in Figure 1. Both of the far ends of this box are
painted with black and white paint, but the painting differs in its orientation. One of the far sides
of the box has vertical stripes, while the other end has horizontal stripes. The middle
compartment is painted solid gray. In addition to the varying visual areas, the CPP chamber also
has different tactile surfaces along the floors of the boxes that help to make the regions more
distinct. One of the compartments features wire-mesh flooring, while the other has roller pin
flooring. The physical and perceptual differences between the compartments plays a crucial role
in the post-conditioning test; the main measure of CPP.
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After the pretest was conducted, we began the conditioning phase of the experiment.
During this portion of the experiment, the wooden dividers are placed back into the CPP
apparatus. This setup can be viewed in Figure 2. Throughout the next five days (the
conditioning phase), subjects were first be administered either a dopamine D2 receptor antagonist
(eticlopride) (0.1 mg/kg, 0.3 mg/kg) or saline (0.1 mg/kg), and, following a 15 minute period to
ensure the drug has been distributed, the same animals will be administered a dose of either
MPH (5 mg/kg) or saline. Approximately ten minutes later, animals were placed into predetermined contexts of the CPP apparatus. The animals spent 10 minutes in the CPP box,
enclosed in one singular compartment so that they cannot explore the other regions of the box.
During the conditioning phase, there were two different sessions; one in the morning and one in
the afternoon. In the morning sessions, we give all 45 animals two injections of saline. This is
to pair one context with saline in the drug condition, and to provide equal exposure to all
contexts across all groups. During the afternoon sessions, animals were given their contextdependent drug treatments, and were placed in the CPP box to elicit proper conditioning. On the
sixth day, when the animals are 38 days of age (P38), we conducted a post-conditioning
preference test where the wooden dividers are removed, and the preference of each animal was
measured. Throughout the entire experiment, the animal’s behavior was tracked using AnyMaze
behavioral scanning software (Stoelting Co, Wood Dale, IL).
The day after the posttest, brain tissue will be taken and analyzed for BDNF
concentrations. The first step in analyzing brain tissue is to kill the animal. In order to preserve
the integrity of the brain tissues that we are trying to retrieve, this death is done as a live
decapitation. This method, while seemingly brutal, allows for a quick and painless death while
also preserving the brain tissue of the subjects. Other common forms of disposal can easily
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affect the brain regions in which we are trying to analyze, effectively defeating the purpose of
the whole experiment. After the rat’s head has been removed, the outer layers of hair, skin, and
the meninges are removed from the top of the head, and the whole brain is removed after
removal of the upper region of the skull. Immediately following removal, the entire brain is
submerged into Isopentain for proper storage. Eventually, we will harvest tissues from the
striatum and the nucleus accumbens and analyze them using an Enzyme Linked Immunosorbent
Assay (ELISA) kit. As previously described, the nucleus accumbens and striatum were chosen
because of their important role in the drug reward pathway, as well as the fact that previous work
in our laboratory using a D1 receptor antagonist also involved taking tissue from these areas. In
addition to tissue analysis, we will compare all of the groups in a between-groups design
ANOVA to compare their means on a statistical level. At the present moment, the BDNF
analysis has not been completed, but will be analyzed at a later time to reap more information
about D2 antagonism in the effects of MPH. Both of these types of post-experiment analysis will
help aid in the comparison of these two studies to help further expand the pharmacological
profile of MPH.
Results
The results from our experiment can be viewed in the appendix in Table 1 and Table 2
and were computed using SPSS. The most important numbers to view in Table 1, the descriptive
statistics table, is the means column, which accords to the preference ratio. The preference ratio
gives us a numerical statistic to represent the strength of a CPP that is formed by the animals,
and is calculated as time spent in their paired context divided by the time spent in both the paired
and non-paired contexts. This ratio can be interpreted as a description of preference, whereas
zero shows complete indifference, and 1.00 shows a total adherence to their contextual area. In
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this column we see that the preference ratios that were formed between the MPH group and the
high dose eticlopride group were similar, with the averages of these groups being 0.644 and
0.664, respectively. As will be discussed in the next section, these two groups both formed a
CPP. Additionally, we can see that the low dose eticlopride group was relatively close to saline
controls, indicating that a CPP was not formed for either group.
In the next table, we have the results from our ANOVA of the preference ratio. This
table shows us that there was a significant main effect of drug treatment (F = 5.152, p =0.004).
This table also demonstrates that the MPH and high dose eticlopride groups were not statistically
significant, but the low dose eticlopride group and the saline group were statistically equivalent.
This implies that the high dose eticlopride group produced a CPP that was equivalent to that of
MPH. In this table we can also see that no sex differences were detected between any of the
groups, even when sex was paired with the antagonist to check for statistical significance.
Lastly, we harvested tissues from the nucleus accumbens and striatum to prepare the
samples for an ELISA. This gives us the ability to quantitatively analyze the BDNF levels
within these areas. Unfortunately, the ELISA results are pending at the moment, and may not be
evaluated until later during the present year. This is in part due to time constraints, but I intend
to amend this paper at a later time in order to add these important results. However, we expect to
see comparable BDNF levels between the high dose eticlopride group and MPH group, due to
the fact that the preference ratios between the MPH and eticlopride groups were very similar. At
this moment, it would be difficult to hypothesize about the BDNF concentrations in striatum and
nucleus accumbens of the saline and low dose eticlopride groups since those groups’ means were
not statistically significant against any other groups.
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Despite the fact that our hypothesis was that the dopamine D2-like antagonist
(eticlopride) would block MPH-induced CPP with greater effect in adolescent males compared to
females, our data suggests that our hypothesis was incorrect. In fact, the animals who were
administered the high dose of eticlopride formed a CPP themselves, in addition to those animals
who were given MPH. However, despite our incorrect hypothesis, these data have important
implications towards MPH addiction.
Discussion
As previously described, our results indicated that both MPH and a high dose (0.03
mg/kg) of eticlopride resulted in CPP in adolescent male and female rats. These results, while
not being hypothesized correctly, actually are consistent with past works on D2 receptors and the
actions of MPH and other psychostimulants. To explain, some D2 antagonist drugs, including
eticlopride, will block all types of D2 receptors that are in the synaptic cleft. In the case of D2
receptors, there are two locations of receptors in the synaptic cleft. Dopamine D2 receptors exist
as both autoreceptors on the presynaptic side of the synaptic cleft, and postsynaptic receptors.
Autoreceptors are the receptors that are found on the presynaptic side, on the presynaptic
terminal where neurotransmitters are released into the synaptic cleft. The D2 autoreceptors play
a role in a feedback loop that modulates the reuptake of excess dopamine in the synaptic cleft
(Dreyer & Hounsgaard, 2013). Eticlopride blocks these inhibitory autoreceptors, which causes
an increase in synaptic dopamine as a result.
In contrast, dopamine D2 are located postsynaptically, and will bind with dopamine.
However, using a high dose of eiclopride will block these receptors as well as the autoreceptors.
Therefore, MPH causes an increase in the amount of dopamine released into the synaptic cleft,
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and eticlopride prevents an increase in the availability of dopamine due to the blocking of the
mechanism responsible for inhibition of dopamine release. This is accomplished via delineation
of autoreceptor functioning. In the case that only the post synaptic D2 receptors would be
blocked, we would expect to see very similar results to those in our D1 study, which was
blockage of MPH-induced CPP. However, eticlopride blocks both presynaptically as well as
postsynaptically located D2 receptors, so we see that CPP was produced, and we can conclude
that D1 antagonism works to block MPH-induced CPP, while D2 antagonism does not.
Furthermore, as can be viewed in Table 1 in the means column, the high dose, or 0.03
mg/kg dose, produced a preference ratio of 0.63 in females, and 0.65 in males. Interestingly,
these numbers are virtually equivalent to the preference ratios that formed in females and males
who were administered MPH (0.65, 0.67, respectively). Nonetheless, the low dose of eticlopride
resembled the results of the saline group, so at a dose of 0.01 mg/kg, the drug may have not
caused full blockage of the D2 receptors. These results help in ushering in the notion of a dosedependent effect in eticlopride-induced CPP.
In attempt to apply these results to real life translationally, we can argue that these results
confirm that MPH, while being relatively safe, is still addictive in nature due to its interactions
with dopamine. Other studies have shown that, despite being the best available medication for
ADHD, patients may still exhibit residual symptoms from the disorder, even after medication has
been added. In order to increase the quality of treatment for ADHD patients, one should first
consider the risks of medicating using methylphenidate. If it is decided that the patient can
properly use MPH, then the addition of a non-pharmacological therapy may help improve their
therapeutic effects. Behavioral therapies such as cognitive-behavioral therapy (CBT), or even
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just the implementation of a regular exercise regimen, have shown to have efficacy in treating
the symptoms of ADHD.
CBT can be described as working with a patient to change their thinking patterns so that
they can relieve the negative emotions that they associate with themselves. This changing in
self-perception and thinking patterns also helps the patient change maladaptive behaviors that
may be exacerbating the symptoms of the disorder. This form of therapy has been identified as
an effective treatment option for the treatment of ADHD, but evidence shows that multimodal
interventions seem to be the most successful for adolescents (Young & Amarsinghe, 2010). For
example, research has shown that CBT may be more effective for adolescents with ADHD and
comorbid anxiety/depression, than in adolescents with ADHD and oppositional defiant disorder
(Antshel, Faraone, & Gordon, 2012). While CBT can often times be used as the sole therapy for
ADHD patients, it should be recommended that pharmacological therapy be added with it to
increase the efficacy of treatment for the patient.
Additionally, another treatment that can be considered is the incorporation of physical
activity. Recent studies have shown that intense aerobic exercise has a positive effect on
children with ADHD symptoms, and this is thought to be due to increases in brain structure and
function as a product of exercise (Berwid, Halperin, 2012).

In one study by Chang, Liu, Yu,

and Lee (2012), the effects of acute physical activity on executive functioning of children with
ADHD were measured using the tests (the Stroop Test and the Wisconsin Card Sorting Test).
Results from this study showed that acute aerobic activity increased ratings on both
neuropsychological tests, and authors postulate that this is due to the brain allocating attention
resources, via influence from the dorsolateral prefrontal cortex, resulting in dopamine release
(Chang, Liu, Yu, & Lee, 2012). This is evidence shows slight effects in the alleviation of ADHD
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symptoms due to decreases in executive function, and should also be considered a viable
treatment additive for adolescents in this category.
In conclusion, the results of our study showed that the dopamine D2 antagonist eticlopride
failed to block MPH-induced CPP and that sex was not influential in the effects of this drug.
When compared to previous work, it seems that D1 antagonism works for blocking the rewarding
effects of methylphenidate, but D2 antagonism does not block these effects. This would indicate
that the D1 receptor is more important for mediating the rewarding effects of MPH. Therefore,
when considering implications of ecological validity, one can argue that this information adds to
the profile of MPH, and shows even more evidence for the similarities between MPH and other
psychostimulants. Further research is needed to assess the role of MPH in mesolimbic system.
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Table 1
Descriptive Statistics
Descriptive Statistics
Dependent Variable: PREFRATIO
ANTAG
0.01ETIC

0.03ETIC

MPH

SAL

Total

SEX

Mean

Std. Deviation

N

F

.5243845

.18281178

7

M

.5456220

.22591350

5

Total
F
M
Total
F
M
Total
F
M
Total
F

.5332334
.6360676
.6518788
.6439732
.6552301
.6725337
.6638819
.4730559
.4507395
.4608833
.5708055

.19211361
.18056022
.13298998
.15141503
.02406915
.03571545
.03012605
.06908358
.06622748
.06509900
.15210493

12
6
6
12
5
5
10
5
6
11
23

M

.5775677

.15421887

22

Total

.5741115

.15142931

45

Note. The differences in the numbers of individuals in each group are due to our pretest results,
and were modified to ensure that no animals showed an initial preference. Additionally, it
should be noted that our previous experiments using D1 antagonism also includes MPH and
saline data, which made it less important to have their number of participants equal to that of the
eticlopride groups.
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Table 2
ANOVA Table
Tests of Between-Subjects Effects
Dependent Variable: PREFRATIO
Source
Corrected Model
Intercept
ANTAG
SEX
ANTAG * SEX
Error
Total
Corrected Total

Type III Sum of
Squares

df

.304a
14.726
.294
.001
.003
.705
15.841
1.009

a. R Squared = .302 (Adjusted R Squared = .170)

Mean Square
7
1
3
1
3
37
45
44

.043
14.726
.098
.001
.001
.019

F
2.284
773.350
5.152
.037
.060

Sig.
.049
.000
.004
.848
.981
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Figure 1
Conditioned Place Preference Boxes- Pretest and Post Test

Note. The picture above shows the conditioned place preference boxes without the wooden
dividers in. This is how the box was set up during the pretest and posttest to allow free roam by
the animals. During the pretest and posttest, the behavioral counts were measured and a
preference ratio was computed.
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Figure 2
Conditioned Place Preference Boxes- Conditioning Trials

Note. During the 5 days of conditioning trials the wooden dividers were inserted, and the
animals were put into one of the four end compartments after they were given their drug
treatment. By doing this, we tether their surroundings with their rewarding effects, or lack
thereof, from the drug treatment. Additionally, the differences in tactile and visual cues, a very
important aspect of our CPP paradigm, can be viewed above.

